| Literature DB >> 28409224 |
Matthias Möhner1, Anne Pohrt2, Johannes Gellissen2.
Abstract
BACKGROUND: While occupational exposure to respirable silica is known to lead to lung disease, most notably silicosis, its association with chronic kidney disease is unclear.Entities:
Keywords: Chronic renal disease; Meta-analysis; Respirable silica; Review; SMR
Mesh:
Substances:
Year: 2017 PMID: 28409224 PMCID: PMC5583269 DOI: 10.1007/s00420-017-1219-x
Source DB: PubMed Journal: Int Arch Occup Environ Health ISSN: 0340-0131 Impact factor: 3.015
Fig. 1Flow chart of the literature search
Industry-based cohort studies
| References | Industry sector, country | Cause of death | Cohort size | Period of employment | Follow-up period | Total deaths | No. of observed cases | Effect size (95%-CI) | Loss to follow-up | Exposure estimation; mean exposure time (in years) |
|---|---|---|---|---|---|---|---|---|---|---|
| Birk et al. ( | Porcelain industry, Germany | Renal diseases (ICD-10: N00–N08, N10–N12, N14–N19, N26–N29) | 8288 | 1895–1987 | 1985–2005 | 1126 | 10 | 1.32 (0.63–2.43) | 7% | Decade of hire, hire before or after the end of 1960, ever having worked in the preparation area; 21.5 |
| Björ et al. ( | Iron ore mining, Sweden | Genitourinary diseases (ICD-10: N00–N99) | 13,000 | 1923–1998 | 1952–2006 | 5185 | 65 | 0.96 (0.74–1.23) | n/a | Duration of employment as blue-collar worker; n/a |
| Brown and Rushton ( | Sand industry, UK | Genitourinary diseases | 2703 | 1950–1986 | 1950–2001 | 764 | 9 | 0.99 (0.45–1.87) | n/a | JEM using samples between 1978 and 2000 and extrapolation back to 1950, n/a |
| Checkoway et al. ( | Diatomaceous earth mining, California, USA | Genitourinary diseases | 2342 | 1942–1987 | 1942–1994 | 749 | 10 | 1.06 (0.51–1.94) | n/a | JEM using measurements between 1948 and 1988 and extrapolation back to 1942; 5.54 |
| Cherry et al. ( | Pottery, Staffordshire, UK | Renal diseases (ICD-9: 581, 582, 583, 585–589) (ICD-10: N03–N05, N18, N19) | 5115 | 1931–1992 | 1985–2008 | 1904 | 14 | 3.5 (1.91–5.87) | 0.6% | Duration of pottery work before 1992, type of pottery work before 1992 for a subgroup of 3506 subjects; 13.8 |
| Koskela et al. ( | Granite industry, Finland | Nephritis, Nephrotic syndrome, Nephrosis, (ICD-8: 580-589) | 1026 | 1940–1971 | 1940–1981 | 235 | 1 | 0.83 (0.02–4.64) | n/a | JEM using RCS samples between 1970 and 1972; 12 |
| McDonald et al. ( | Sand industry, USA | Nephritis/nephrosis (ICD-9: 580.0–589.9) | 2452 | 1940–1979 | 1940–2000 | 1221 | 18 | 2.80 (1.66–4.42) | 0.9% | JEM using RCS samples between 1975 and present, interpolation to changes and particle counts from 1946 to 1955; n/a |
| Morfeld et al. ( | Hard coal mining, Germany | Renal diseases (ICD-9: 580–587) | 4579 | 1980–2002 | 1980–2002 | 1183 | 13 | 1.13 (0.60–1.93) | 0.5% | JEM based on measurements 1980–2001; 30.4 |
| Olsen et al. ( | Roofing granule production, USA | Renal diseases | 2650 | 1945–2004 | 1945–2004 | 772 | 16 | 1.76 (1.01–2.86) | 0.9% | JEM (based mainly on expert judgements); 11.2 |
| Reid and Sluis-Cremer ( | Gold mining, South Africa | Renal failure (ICD-9: 580–589) | 4925 | At work 1970 | 1970–1989 | 2032 | 24 | 1.64 (1.05–2.43) | 1% | JEM, total duration of underground service, n/a |
| Steenland and Brown ( | Gold mining, South Dakota, USA | a)Acute renal disease (ICD-9: 580–581, 584), b) Chronic renal disease (ICD-9: 582–583, 585–587) | 3328 | 1940–1975 | 1940–1990 | 1551 | (a) 2 | (a) 1.19 (0.14–4.29) | 2% | JEM; 9 |
| Steenland and Sanderson ( | Sand industry, USA | a) Acute renal disease (ICD-9: 580–581, 584), | 4626 | 1960–1997 | 1960–1997 | 1073 | (a) 3 | (a) 3.37 (0.70–9.86) | n/a | JEM based on measurements 1974–1996, estimates for 1946 and interpolation; 9 |
| Vacek et al. ( | Granite industry, Vermont, USA | Nephritis and nephrosis | 7052 | 1947–1998 | 1947–2004 | 3831 | 34 | 0.99 (0.68–1.38) | 1.25% | JEM based on measurements between 1924 and 2004; n/a |
n/a not available
Cohort studies based on registries of silicotics
| References | Geographical region | Outcome | Cohort size | Diagnostic period for silicosis | Follow-up period | Total deaths | Number of observed cases | Effect size (95%-CI) |
|---|---|---|---|---|---|---|---|---|
| Amandus et al. ( | North Carolina, USA | Mortality from chronic and unspecific failure of kidney (ICD8: 582–584) | 760 | 1940–1983 | 1940–1983 | 550 | 2 | 1.4 (0.17–5.16) |
| Brown et al. ( | Sweden, Denmark | Mortality from urinary diseases | 1130 | SE: 1965–1883, | SE: 1965–1989, | 795 | 9 | 1.6 (0.7–3.1) |
| Ebihara and Kawami ( | Japan | Mortality from nephritis and nephrosis (ICD9: 580–589) | 850 | 1958–1995 | 1958–1995 | 599 | 5 | 1.13 (0.37–2.63) |
| Forastiere et al. ( | Latium, Italy | Mortality from genitourinary diseases (ICD-9: 580–629) | 952 | 1946–1984 | 1969–1984 | 607 | 9 | 1.0 (0.46–1.9) |
| Marinaccio et al. ( | Tuscany, Italy | Mortality from nephritis, nephrotic syndrome, and nephrosis | 14,929 | 1946–1979 | 1980–1999 | 8521 | 65 | 0.94 (0.73–1.20) |
| Ng et al. ( | Hongkong | Mortality from genitourinary diseases (ICD9: 580–629) | 1419 | 1965–1981 | 1980–1986 | 356 | 2 | 0.49 (0.06–1.77) |
| Scarselli et al. ( | Latium, Italy | Mortality from nephritis, nephrotic syndrome, and nephrosis (ICD9: 580–589) | 2034 | 1943–1986 | 1997–2006 | 1258 | 12 | 1.06 (0.55–1.86) |
| Starzynski et al. ( | Poland | Mortality from nephritis, nephrotic syndrome, and nephrosis (ICD9: 580–589) | 11,935 | 1970–1985 | 1970–1991 | 3141 | 33 | 1.22 (0.84–1.71) |
| Steenland et al. ( | USA | (a) Registration of ESRD | 1328 | 1984–1998 | 1984–1998 | 764 | (a) 9 | (a) 1.67 (0.76–3.17) |
| Yu et al. ( | Hong Kong | Mortality from kidney disease (ICD9: 584–586) | 2789 | 1981–1998 | 1981–1999 | 853 | 3 | 0.27 (0.05–0.78) |
case–control studies
| References | Geographical region | Study specification | Outcome | Number of subjects (cases/controls) | Period of recruitment | Response rates (among cases/among controls) % | OR (95%-CI) |
|---|---|---|---|---|---|---|---|
| Calvert et al. ( | 27 states of USA | Individually matched study; five controls matched to each case based on sex, race, state of residence, five-year age group, and year of death group | Mortality: | a) 47,942/239,644 | 1982–1995 | 100/100 | a) 0.67 (0.32–1.39) |
| Chiazze et al. ( | US. glass wool production plants | Nested case–control study; controls matched by plant, year of birth (±2 | Mortality; nephritis/nephrosis (ICD-9: 580–589): | a) 15/48 | Until 1994 | 100/100 | a) 1.57 (0.07–46.73); |
| Steenland et al. ( | Michigan, USA | Controls pair-matched to cases by age, race, and area of residence | Incidence; selected diagnoses of ESRD (glomerulonephritis, nephrosclerosis, and interstitial kidney disease) | 325/325 | 1976–1984 | 69/61 | 1.67 (1.02–2.74) |
| Vupputuri et al. ( | North Carolina, USA | Community controls are matched by age (±5 | Incidence of chronic renal disease (ICD-9: 250.4, 403, 404, 582–587, 590.0, 590.8, 593.9) | 504/457 | 1980–1982 | 78/73 | Chronic renal disease: 1.37 (1.02–1.85); |
Fig. 2Meta-analysis of cohort studies on silicotics
Fig. 3Meta-analysis of industry-based cohort studies
Assessment of risk of bias and studies’ value for evidence
| Study | Bias due to | Study power | Statistical methods | Completeness of the reporting | Overall value for evidence | ||||
|---|---|---|---|---|---|---|---|---|---|
| Selection | Measurement of outcome | Exposure assessment | Confounding | Missing data | |||||
| Industrial cohorts | |||||||||
| Birk et al. ( | ** | *** | *** | *** | ** | ++ | +++ | +++ | ++ |
| Björ et al. ( | **** | ** | *** | *** | *** | +++ | +++ | ++ | +++ |
| Brown and Rushton ( | **** | ** | **** | *** | *** | ++ | +++ | +++ | ++ |
| Checkoway et al. ( | **** | ** | **** | *** | *** | ++ | +++ | +++ | ++ |
| Cherry et al. ( | **** | *** | **** | *** | **** | ++ | +++ | ++++ | +++ |
| Koskela et al. ( | **** | *** | ** | *** | *** | + | ++ | +++ | ++ |
| McDonald et al. ( | **** | *** | **** | *** | *** | ++ | +++ | +++ | ++ |
| Morfeld et al. ( | ** | *** | **** | *** | **** | ++ | +++ | ++++ | ++ |
| Olsen et al. ( | **** | *** | **** | *** | **** | ++ | +++ | ++++ | ++ |
| Reid and Sluis-Cremer ( | ** | *** | ** | ** | **** | ++ | ++ | ++ | ++ |
| Steenland and Brown ( | **** | **** | **** | ** | **** | ++ | +++ | +++ | ++ |
| Steenland and Sanderson ( | *** | **** | **** | ** | *** | ++ | +++ | +++ | +++ |
| Vacek et al. ( | **** | *** | **** | *** | **** | +++ | ++++ | ++++ | +++ |
| Cohorts of silicotics | |||||||||
| Amandus et al. ( | *** | *** | ** | ** | *** | + | +++ | +++ | ++ |
| Brown et al. ( | *** | ** | ** | ** | *** | ++ | +++ | +++ | ++ |
| Ebihara and Kawami ( | *** | *** | ** | ** | *** | ++ | +++ | +++ | ++ |
| Forastiere et al. ( | *** | ** | ** | ** | *** | ++ | +++ | +++ | ++ |
| Marinaccio et al. ( | *** | *** | ** | ** | *** | +++ | +++ | +++ | +++ |
| Ng et al. ( | *** | ** | ** | ** | *** | + | +++ | +++ | + |
| Scarselli et al. ( | *** | *** | ** | ** | *** | ++ | +++ | +++ | ++ |
| Starzynski et al. ( | *** | *** | ** | *** | **** | +++ | +++ | +++ | +++ |
| Steenland et al. ( | *** | **** | ** | ** | *** | ++ | +++ | +++ | ++ |
| Yu et al. ( | *** | *** | *** | ** | *** | + | +++ | +++ | + |
| Case–control studies | |||||||||
| Calvert et al. ( | **** | **** | ** | ** | ** | ++++ | +++ | +++ | +++ |
| Chiazze et al. ( | **** | **** | *** | *** | *** | ++ | +++ | +++ | ++ |
| Steenland et al. ( | ** | **** | ** | *** | *** | +++ | +++ | +++ | ++ |
| Vupputuri et al. ( | *** | **** | ** | *** | *** | ++++ | +++ | +++ | +++ |
* Critical risk, **** low risk
+ Low, ++++ high